Premium
Administration of high‐dose interleukin‐2 in a 2‐year‐old with metastatic melanoma
Author(s) -
Bernhardt M. Brooke,
Hicks M. John,
Pappo Alberto S.
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22255
Subject(s) - medicine , metastatic melanoma , blood cancer , melanoma , interleukin 2 , disease , oncology , metastasis , cancer , pediatrics , cancer research , cytokine
Malignant melanoma is rare in pediatrics, and therapies for patients with disseminated disease have not been well studied. This report describes our experience with the use of high‐dose interleukin 2 (aldesleukin, IL‐2) in a 2‐year‐old child with metastatic melanoma and describes our approach for the administration of this agent to young patients. Pediatr Blood Cancer 2009; 53:1346–1348. © 2009 Wiley‐Liss, Inc.